Related references
Note: Only part of the references are listed.Structure-activity relationship (SAR) studies on substituted N-(pyridin-3-yl)-2-amino-isonicotinamides as highly potent and selective glycogen synthase kinase-3 (GSK-3) inhibitors
Guanglin Luo et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2023)
An updated research of glycogen synthase kinase-3β inhibitors: a review
Shan-Kui Liu et al.
MONATSHEFTE FUR CHEMIE (2021)
Software for the frontiers of quantum chemistry: An overview of developments in the Q-Chem 5 package
Evgeny Epifanovsky et al.
JOURNAL OF CHEMICAL PHYSICS (2021)
Glycogen Synthase Kinase 3 (GSK3): Its Role and Inhibitors
Pankaj Wadhwa et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2020)
Optimization of Indazole-Based GSK-3 Inhibitors with Mitigated hERG Issue and In Vivo Activity in a Mood Disorder Model
Federica Prati et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment
Giuseppa Augello et al.
CELLS (2020)
2020 Alzheimer's disease facts and figures
[Anonymous]
ALZHEIMERS & DEMENTIA (2020)
Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3β inhibitors: A critical review
M. Xu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses
Ilyas Sahin et al.
CANCER BIOLOGY & THERAPY (2019)
Structural Basis for Achieving GSK-3β Inhibition with High Potency, Selectivity, and Brain Exposure for Positron Emission Tomography Imaging and Drug Discovery
Vadim Bernard-Gauthier et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions
A. Prasanth Saraswati et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Natural and synthetic bioactive inhibitors of glycogen synthase kinase
Imran Khan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
GSK3 Inhibitors in the Therapeutic Development of Diabetes, Cancer and Neurodegeneration: Past, Present and Future
Mudasir Maqbool et al.
CURRENT PHARMACEUTICAL DESIGN (2017)
Discovery of novel 2-(4-aryl-2-methylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3β inhibitors
Toshiyuki Kohara et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Discovery of novel 2-(3-phenylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3β inhibitors
Yoshihiro Usui et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery
Travis T. Wager et al.
ACS CHEMICAL NEUROSCIENCE (2016)
Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging
Steven H. Liang et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease
Mudasir Maqbool et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Discovery of Isonicotinamides as Highly Selective, Brain Penetrable, and Orally Active Glycogen Synthase Kinase-3 Inhibitors
Guanglin Luo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)pyrimidin-4(3H)-ones as orally-active GSK-3β inhibitors for Alzheimer's disease
Kenji Fukunaga et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core
Prasanna Sivaprakasam et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Glycogen synthase kinase 3 in Wnt signaling pathway and cancer
Nydia Tejeda-Munoz et al.
IUBMB LIFE (2015)
Hit Optimization of 5-Substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: Potent Glycogen Synthase Kinase-3 (GSK-3) Inhibitors with in Vivo Activity in Model of Mood Disorders
Guido Furlotti et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
A Phase II Trial of Tideglusib in Alzheimer's Disease
Simon Lovestone et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
The GSK-3 Family as Therapeutic Target for Myocardial Diseases
Hind Lal et al.
CIRCULATION RESEARCH (2015)
The role of ligand efficiency metrics in drug discovery
Andrew L. Hopkins et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
GSK-3β, a pivotal kinase in Alzheimer disease
Maria Llorens-Martin et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2014)
2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; A new class of potent, selective and orally active glycogen synthase kinase-3β inhibitors
Kenji Fukunaga et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
6-(4-Pyridyl)pyrimidin-4(3H)-ones as CNS penetrant glycogen synthase kinase-3β inhibitors
Fumiaki Uehara et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Roles of Glycogen Synthase Kinase 3 in Alzheimer's Disease
Zhiyou Cai et al.
CURRENT ALZHEIMER RESEARCH (2012)
Discovery of Novel Potent and Highly Selective Glycogen Synthase Kinase-3β (GSK3β) Inhibitors for Alzheimer's Disease: Design, Synthesis, and Characterization of Pyrazines
Stefan Berg et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
6-Amino-4-(pyrimidin-4-yl)pyridones: Novel glycogen synthase kinase-3β inhibitors
Karen Coffman et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S)-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease
Tomohiro Onishi et al.
JOURNAL OF NEUROCHEMISTRY (2011)
Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties
Travis T. Wager et al.
ACS CHEMICAL NEUROSCIENCE (2010)
Design of potent and selective GSK3β inhibitors with acceptable safety profile and pharmacokinetics
Dominique Lesuisse et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors
Jesus Avila et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2010)
Efficacy of a novel, orally active GSK-3 inhibitor 6-Methyl-N-[3-[[3-(1-methylethoxy)propyl]carbamoyl]-1H-pyrazol-4-yl]pyridine-3-carboxamide in tau transgenic mice
Yumiko Uno et al.
BRAIN RESEARCH (2009)
2-{3-[4-(Alkylsulfinyl)phenyl]-1-benzofuran-5-yl}-5-methyl-1,3,4-oxadiazole Derivatives as Novel Inhibitors of Glycogen Synthase Kinase-3β with Good Brain Permeability
Morihisa Saitoh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman et al.
NATURE BIOTECHNOLOGY (2008)
Preclinical efficacy on GSK-3 inhibitors: Towards a future generation of powerful drugs
Ana Martinez
MEDICINAL RESEARCH REVIEWS (2008)
Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation
M-L Selenica et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Lithium reduces tau phosphorylation but not Aβ or working memory deficits in a transgenic model with both plaques and tangles
Antonella Caccamo et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder
Michael K. Rowe et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2007)
Glycogen synthase kinase-3 - An overview of an over-achieving protein kinase
Lisa Kockeritz et al.
CURRENT DRUG TARGETS (2006)
Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo
W Noble et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
The development of potent and selective bisarylmaleimide GSK3 inhibitors
TA Engler et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
Pharmacological inhibitors of glycogen synthase kinase 3
L Meijer et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2004)
Substituted 3-imidazo[1,2-a]pyridin-3-yl-4-(1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3
TA Engler et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Design, synthesis, and biological evaluation of novel 7-azaindolyl-heteroaryl-maleimides as potent and selective glycogen synthase kinase-3β (GSK-3β) inhibitors
DJ O'Neill et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2004)
Triple-transgenic model of Alzheimer's disease with plaques and tangles:: Intracellular Aβ and synaptic dysfunction
S Oddo et al.
NEURON (2003)
Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factors
KA Longo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Modelling Alzheimer-specific abnormal Tau phosphorylation independently of GSK3β and PKA kinase activities
P Delobel et al.
FEBS LETTERS (2002)
The multifaceted roles of glycogen synthase kinase 3β in cellular signaling
CA Grimes et al.
PROGRESS IN NEUROBIOLOGY (2001)
Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties
P Ertl et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Paullones are potent inhibitors of glycogen synthase kinase-3β and cyclin-dependent kinase 5/p25
M Leost et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2000)
Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription
MP Coghlan et al.
CHEMISTRY & BIOLOGY (2000)
Two different signal transduction pathways are implicated in the regulation of initiation factor 2B activity in insulin-like growth factor-1-stimulated neuronal cells
C Quevedo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes
SE Nikoulina et al.
DIABETES (2000)
Share Paper
